B-Cell Non-Hodgkin Lymphoma: BI-1206 Treatment Study

We are studying a new monoclonal antibody combined with rituximab, with or without acalabrutinib, for patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The goal is to assess safety and how well it may work in reducing cancer cells.

3-6 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOralInjectionOncology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Calquence
Calquence is a cancer medicine used to treat certain blood cancers, such as chronic lymphocytic leukemia and mantle cell lymphoma.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Acalabrutinib
Acalabrutinib is a substance that blocks a protein in B cells to treat certain B‑cell blood cancers.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Bi-1206

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Krankenhaus Nordwest GmbH
Institut für Klinisch-Onkologische Forschung (IKF)
Eschborn, Germany
Robert Bosch Krankenhaus GmbH
Department of Hematology, Oncology and Palliative Care
Stuttgart, Germany
Institut Catala D'oncologia
Department of Hematology
Badalona, Spain
Sponsor: BioInvent International AB
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.